First-line intra-arterial versus intravenous chemotherapy in unilateral sporadic group D retinoblastoma: evidence of better visual outcomes, ocular survival and shorter time to success with intra-arterial delivery from retrospective review of 20 years of treatment
PurposeThe introduction of intra-arterial chemotherapy (IAC) as salvage treatment has improved the prognosis for eye conservation in group D retinoblastoma. The aim of this study was to compare the outcomes of consecutive patients with advanced unilateral disease treated with either first-line intra...
Gespeichert in:
| Veröffentlicht in: | British journal of ophthalmology 2017-08, Vol.101 (8), p.1086-1093 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1093 |
|---|---|
| container_issue | 8 |
| container_start_page | 1086 |
| container_title | British journal of ophthalmology |
| container_volume | 101 |
| creator | Munier, Francis L Mosimann, Pascal Puccinelli, Francesco Gaillard, Marie-Claire Stathopoulos, Christina Houghton, Susan Bergin, Ciara Beck-Popovic, Maja |
| description | PurposeThe introduction of intra-arterial chemotherapy (IAC) as salvage treatment has improved the prognosis for eye conservation in group D retinoblastoma. The aim of this study was to compare the outcomes of consecutive patients with advanced unilateral disease treated with either first-line intravenous chemotherapy (IVC) or first-line IAC.DesignThis is a retrospective mono-centric comparative review of consecutive patients.PatientsSporadic unilateral retinoblastoma group D cases treated conservatively at Jules-Gonin Eye Hospital and CHUV between 1997 and 2014. From January 1997 to August 2008, IVC, combined with focal treatments, was the primary treatment approach. From September 2008 to October 2014, IAC replaced IVC as first-line therapy.Methods48 patients met the inclusion criteria, receiving only either IAC or IVC as primary treatment modality.ResultsOutcomes of 23 patients treated by IVC were compared with those of 25 treated by IAC; mean follow-up was 105.3 months (range 29.2–218.6) and 41.7 months (range 19.6–89.5), respectively. Treatment duration was significantly shorter in the IAC group (p |
| doi_str_mv | 10.1136/bjophthalmol-2016-309298 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5537510</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1847881108</sourcerecordid><originalsourceid>FETCH-LOGICAL-b422t-5d972a9997e3b00fbc7d7cf86ec1e3a9e5b44b35d45e4b8ab42c17188cc3d5f93</originalsourceid><addsrcrecordid>eNqNUk1v1TAQDAhEXwt_AVniwoGAnS_bHJBQoYBUiQucLdvZNH6y42A7qd6NC3-UX4KjV6rSE6d4d2fGs84UBSL4NSF190bt_TymUVrnbVlh0pU15hVnD4sdaTqWW5Q_KnYYY1oS0pGT4jTGfS6rjtAnxUlFeUU7ynYPTi9MiKm0ZgJkphRkKUOCYKRFK4S4xGN3hcnnsx7B-TRCkPMhD9AyGSszPKPj7IPsjUZXwS8z-oACJDN5ZWVM3sm3CFbTw6QB-QEpSJmFVhOXTPVL0t5BfIW8XqwMKC5hNWueyKlHcfSbI5SMA5R8HmoNMaJrk8b7lnuwJts-oCF4tzkIPs6gU27majVwvd1e4d8_fx1AhrhVKYBMDqb0tHg8SBvh2c33rPh-8fHb-efy8uunL-fvL0vVVFUq257TSnLOKdQK40Fp2lM9sA40gVpyaFXTqLrtmxYaxWRmaUIJY1rXfTvw-qx4d9SdF-Wg17DtYMUcjJPhILw04t_JZEZx5VfRtjVtCc4CL28Egv-xQEzCmajBWjlB_kuCsIYyRghmGfriHnTvlzDl9QThhLMWdxXNKHZE6fxeMcBwa4ZgsQVO3A2c2AInjoHL1Od3l7kl_k1YBtRHgHL7_5f9AzF68cw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1919850627</pqid></control><display><type>article</type><title>First-line intra-arterial versus intravenous chemotherapy in unilateral sporadic group D retinoblastoma: evidence of better visual outcomes, ocular survival and shorter time to success with intra-arterial delivery from retrospective review of 20 years of treatment</title><source>MEDLINE</source><source>PubMed Central</source><creator>Munier, Francis L ; Mosimann, Pascal ; Puccinelli, Francesco ; Gaillard, Marie-Claire ; Stathopoulos, Christina ; Houghton, Susan ; Bergin, Ciara ; Beck-Popovic, Maja</creator><creatorcontrib>Munier, Francis L ; Mosimann, Pascal ; Puccinelli, Francesco ; Gaillard, Marie-Claire ; Stathopoulos, Christina ; Houghton, Susan ; Bergin, Ciara ; Beck-Popovic, Maja</creatorcontrib><description>PurposeThe introduction of intra-arterial chemotherapy (IAC) as salvage treatment has improved the prognosis for eye conservation in group D retinoblastoma. The aim of this study was to compare the outcomes of consecutive patients with advanced unilateral disease treated with either first-line intravenous chemotherapy (IVC) or first-line IAC.DesignThis is a retrospective mono-centric comparative review of consecutive patients.PatientsSporadic unilateral retinoblastoma group D cases treated conservatively at Jules-Gonin Eye Hospital and CHUV between 1997 and 2014. From January 1997 to August 2008, IVC, combined with focal treatments, was the primary treatment approach. From September 2008 to October 2014, IAC replaced IVC as first-line therapy.Methods48 patients met the inclusion criteria, receiving only either IAC or IVC as primary treatment modality.ResultsOutcomes of 23 patients treated by IVC were compared with those of 25 treated by IAC; mean follow-up was 105.3 months (range 29.2–218.6) and 41.7 months (range 19.6–89.5), respectively. Treatment duration was significantly shorter in the IAC group (p<0.001). Ten eyes in the IVC group underwent enucleation. Recordable visual acuity of the salvaged eyes was significantly better in the IAC group (0.9 vs 1.4 logarithm of the minimum angle of resolution, p<0.01). No extraocular disease, metastases or long-term systemic complications were observed in either group.ConclusionsThe difference in the time frame between treatment groups had an impact on the availability of intravitreal chemotherapy treatment. Despite this, the results reported here imply that eyes treated with first-line IAC will have shorter treatment period, better ocular survival and visual acuity than first-line IVC.</description><identifier>ISSN: 0007-1161</identifier><identifier>EISSN: 1468-2079</identifier><identifier>DOI: 10.1136/bjophthalmol-2016-309298</identifier><identifier>PMID: 27927678</identifier><language>eng</language><publisher>England: BMJ Publishing Group LTD</publisher><subject><![CDATA[Aftercare ; Antineoplastic Combined Chemotherapy Protocols - administration & dosage ; Cancer ; Carboplatin - administration & dosage ; Carotid arteries ; Chemotherapy ; Child ; Child, Preschool ; Childrens health ; Classification ; Clinical Science ; Cryotherapy ; Etoposide - administration & dosage ; Humans ; Infant ; Infusions, Intra-Arterial ; Infusions, Intravenous ; Medical prognosis ; Melphalan - administration & dosage ; Ophthalmology ; Pediatrics ; Retina ; Retinal Neoplasms - drug therapy ; Retinoblastoma ; Retinoblastoma - drug therapy ; Retrospective Studies ; Salvage Therapy - methods ; Treatment Outcome ; Tumors ; Veins & arteries ; Vision Disorders - prevention & control]]></subject><ispartof>British journal of ophthalmology, 2017-08, Vol.101 (8), p.1086-1093</ispartof><rights>Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing</rights><rights>Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.</rights><rights>Copyright: 2016 Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing</rights><rights>Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ 2016</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b422t-5d972a9997e3b00fbc7d7cf86ec1e3a9e5b44b35d45e4b8ab42c17188cc3d5f93</citedby><cites>FETCH-LOGICAL-b422t-5d972a9997e3b00fbc7d7cf86ec1e3a9e5b44b35d45e4b8ab42c17188cc3d5f93</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5537510/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5537510/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27927678$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Munier, Francis L</creatorcontrib><creatorcontrib>Mosimann, Pascal</creatorcontrib><creatorcontrib>Puccinelli, Francesco</creatorcontrib><creatorcontrib>Gaillard, Marie-Claire</creatorcontrib><creatorcontrib>Stathopoulos, Christina</creatorcontrib><creatorcontrib>Houghton, Susan</creatorcontrib><creatorcontrib>Bergin, Ciara</creatorcontrib><creatorcontrib>Beck-Popovic, Maja</creatorcontrib><title>First-line intra-arterial versus intravenous chemotherapy in unilateral sporadic group D retinoblastoma: evidence of better visual outcomes, ocular survival and shorter time to success with intra-arterial delivery from retrospective review of 20 years of treatment</title><title>British journal of ophthalmology</title><addtitle>Br J Ophthalmol</addtitle><description>PurposeThe introduction of intra-arterial chemotherapy (IAC) as salvage treatment has improved the prognosis for eye conservation in group D retinoblastoma. The aim of this study was to compare the outcomes of consecutive patients with advanced unilateral disease treated with either first-line intravenous chemotherapy (IVC) or first-line IAC.DesignThis is a retrospective mono-centric comparative review of consecutive patients.PatientsSporadic unilateral retinoblastoma group D cases treated conservatively at Jules-Gonin Eye Hospital and CHUV between 1997 and 2014. From January 1997 to August 2008, IVC, combined with focal treatments, was the primary treatment approach. From September 2008 to October 2014, IAC replaced IVC as first-line therapy.Methods48 patients met the inclusion criteria, receiving only either IAC or IVC as primary treatment modality.ResultsOutcomes of 23 patients treated by IVC were compared with those of 25 treated by IAC; mean follow-up was 105.3 months (range 29.2–218.6) and 41.7 months (range 19.6–89.5), respectively. Treatment duration was significantly shorter in the IAC group (p<0.001). Ten eyes in the IVC group underwent enucleation. Recordable visual acuity of the salvaged eyes was significantly better in the IAC group (0.9 vs 1.4 logarithm of the minimum angle of resolution, p<0.01). No extraocular disease, metastases or long-term systemic complications were observed in either group.ConclusionsThe difference in the time frame between treatment groups had an impact on the availability of intravitreal chemotherapy treatment. Despite this, the results reported here imply that eyes treated with first-line IAC will have shorter treatment period, better ocular survival and visual acuity than first-line IVC.</description><subject>Aftercare</subject><subject>Antineoplastic Combined Chemotherapy Protocols - administration & dosage</subject><subject>Cancer</subject><subject>Carboplatin - administration & dosage</subject><subject>Carotid arteries</subject><subject>Chemotherapy</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Childrens health</subject><subject>Classification</subject><subject>Clinical Science</subject><subject>Cryotherapy</subject><subject>Etoposide - administration & dosage</subject><subject>Humans</subject><subject>Infant</subject><subject>Infusions, Intra-Arterial</subject><subject>Infusions, Intravenous</subject><subject>Medical prognosis</subject><subject>Melphalan - administration & dosage</subject><subject>Ophthalmology</subject><subject>Pediatrics</subject><subject>Retina</subject><subject>Retinal Neoplasms - drug therapy</subject><subject>Retinoblastoma</subject><subject>Retinoblastoma - drug therapy</subject><subject>Retrospective Studies</subject><subject>Salvage Therapy - methods</subject><subject>Treatment Outcome</subject><subject>Tumors</subject><subject>Veins & arteries</subject><subject>Vision Disorders - prevention & control</subject><issn>0007-1161</issn><issn>1468-2079</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>9YT</sourceid><sourceid>ACMMV</sourceid><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNqNUk1v1TAQDAhEXwt_AVniwoGAnS_bHJBQoYBUiQucLdvZNH6y42A7qd6NC3-UX4KjV6rSE6d4d2fGs84UBSL4NSF190bt_TymUVrnbVlh0pU15hVnD4sdaTqWW5Q_KnYYY1oS0pGT4jTGfS6rjtAnxUlFeUU7ynYPTi9MiKm0ZgJkphRkKUOCYKRFK4S4xGN3hcnnsx7B-TRCkPMhD9AyGSszPKPj7IPsjUZXwS8z-oACJDN5ZWVM3sm3CFbTw6QB-QEpSJmFVhOXTPVL0t5BfIW8XqwMKC5hNWueyKlHcfSbI5SMA5R8HmoNMaJrk8b7lnuwJts-oCF4tzkIPs6gU27majVwvd1e4d8_fx1AhrhVKYBMDqb0tHg8SBvh2c33rPh-8fHb-efy8uunL-fvL0vVVFUq257TSnLOKdQK40Fp2lM9sA40gVpyaFXTqLrtmxYaxWRmaUIJY1rXfTvw-qx4d9SdF-Wg17DtYMUcjJPhILw04t_JZEZx5VfRtjVtCc4CL28Egv-xQEzCmajBWjlB_kuCsIYyRghmGfriHnTvlzDl9QThhLMWdxXNKHZE6fxeMcBwa4ZgsQVO3A2c2AInjoHL1Od3l7kl_k1YBtRHgHL7_5f9AzF68cw</recordid><startdate>20170801</startdate><enddate>20170801</enddate><creator>Munier, Francis L</creator><creator>Mosimann, Pascal</creator><creator>Puccinelli, Francesco</creator><creator>Gaillard, Marie-Claire</creator><creator>Stathopoulos, Christina</creator><creator>Houghton, Susan</creator><creator>Bergin, Ciara</creator><creator>Beck-Popovic, Maja</creator><general>BMJ Publishing Group LTD</general><general>BMJ Publishing Group</general><scope>9YT</scope><scope>ACMMV</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20170801</creationdate><title>First-line intra-arterial versus intravenous chemotherapy in unilateral sporadic group D retinoblastoma: evidence of better visual outcomes, ocular survival and shorter time to success with intra-arterial delivery from retrospective review of 20 years of treatment</title><author>Munier, Francis L ; Mosimann, Pascal ; Puccinelli, Francesco ; Gaillard, Marie-Claire ; Stathopoulos, Christina ; Houghton, Susan ; Bergin, Ciara ; Beck-Popovic, Maja</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b422t-5d972a9997e3b00fbc7d7cf86ec1e3a9e5b44b35d45e4b8ab42c17188cc3d5f93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Aftercare</topic><topic>Antineoplastic Combined Chemotherapy Protocols - administration & dosage</topic><topic>Cancer</topic><topic>Carboplatin - administration & dosage</topic><topic>Carotid arteries</topic><topic>Chemotherapy</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Childrens health</topic><topic>Classification</topic><topic>Clinical Science</topic><topic>Cryotherapy</topic><topic>Etoposide - administration & dosage</topic><topic>Humans</topic><topic>Infant</topic><topic>Infusions, Intra-Arterial</topic><topic>Infusions, Intravenous</topic><topic>Medical prognosis</topic><topic>Melphalan - administration & dosage</topic><topic>Ophthalmology</topic><topic>Pediatrics</topic><topic>Retina</topic><topic>Retinal Neoplasms - drug therapy</topic><topic>Retinoblastoma</topic><topic>Retinoblastoma - drug therapy</topic><topic>Retrospective Studies</topic><topic>Salvage Therapy - methods</topic><topic>Treatment Outcome</topic><topic>Tumors</topic><topic>Veins & arteries</topic><topic>Vision Disorders - prevention & control</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Munier, Francis L</creatorcontrib><creatorcontrib>Mosimann, Pascal</creatorcontrib><creatorcontrib>Puccinelli, Francesco</creatorcontrib><creatorcontrib>Gaillard, Marie-Claire</creatorcontrib><creatorcontrib>Stathopoulos, Christina</creatorcontrib><creatorcontrib>Houghton, Susan</creatorcontrib><creatorcontrib>Bergin, Ciara</creatorcontrib><creatorcontrib>Beck-Popovic, Maja</creatorcontrib><collection>BMJ Open Access Journals</collection><collection>BMJ Journals:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>British journal of ophthalmology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Munier, Francis L</au><au>Mosimann, Pascal</au><au>Puccinelli, Francesco</au><au>Gaillard, Marie-Claire</au><au>Stathopoulos, Christina</au><au>Houghton, Susan</au><au>Bergin, Ciara</au><au>Beck-Popovic, Maja</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>First-line intra-arterial versus intravenous chemotherapy in unilateral sporadic group D retinoblastoma: evidence of better visual outcomes, ocular survival and shorter time to success with intra-arterial delivery from retrospective review of 20 years of treatment</atitle><jtitle>British journal of ophthalmology</jtitle><addtitle>Br J Ophthalmol</addtitle><date>2017-08-01</date><risdate>2017</risdate><volume>101</volume><issue>8</issue><spage>1086</spage><epage>1093</epage><pages>1086-1093</pages><issn>0007-1161</issn><eissn>1468-2079</eissn><abstract>PurposeThe introduction of intra-arterial chemotherapy (IAC) as salvage treatment has improved the prognosis for eye conservation in group D retinoblastoma. The aim of this study was to compare the outcomes of consecutive patients with advanced unilateral disease treated with either first-line intravenous chemotherapy (IVC) or first-line IAC.DesignThis is a retrospective mono-centric comparative review of consecutive patients.PatientsSporadic unilateral retinoblastoma group D cases treated conservatively at Jules-Gonin Eye Hospital and CHUV between 1997 and 2014. From January 1997 to August 2008, IVC, combined with focal treatments, was the primary treatment approach. From September 2008 to October 2014, IAC replaced IVC as first-line therapy.Methods48 patients met the inclusion criteria, receiving only either IAC or IVC as primary treatment modality.ResultsOutcomes of 23 patients treated by IVC were compared with those of 25 treated by IAC; mean follow-up was 105.3 months (range 29.2–218.6) and 41.7 months (range 19.6–89.5), respectively. Treatment duration was significantly shorter in the IAC group (p<0.001). Ten eyes in the IVC group underwent enucleation. Recordable visual acuity of the salvaged eyes was significantly better in the IAC group (0.9 vs 1.4 logarithm of the minimum angle of resolution, p<0.01). No extraocular disease, metastases or long-term systemic complications were observed in either group.ConclusionsThe difference in the time frame between treatment groups had an impact on the availability of intravitreal chemotherapy treatment. Despite this, the results reported here imply that eyes treated with first-line IAC will have shorter treatment period, better ocular survival and visual acuity than first-line IVC.</abstract><cop>England</cop><pub>BMJ Publishing Group LTD</pub><pmid>27927678</pmid><doi>10.1136/bjophthalmol-2016-309298</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-1161 |
| ispartof | British journal of ophthalmology, 2017-08, Vol.101 (8), p.1086-1093 |
| issn | 0007-1161 1468-2079 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5537510 |
| source | MEDLINE; PubMed Central |
| subjects | Aftercare Antineoplastic Combined Chemotherapy Protocols - administration & dosage Cancer Carboplatin - administration & dosage Carotid arteries Chemotherapy Child Child, Preschool Childrens health Classification Clinical Science Cryotherapy Etoposide - administration & dosage Humans Infant Infusions, Intra-Arterial Infusions, Intravenous Medical prognosis Melphalan - administration & dosage Ophthalmology Pediatrics Retina Retinal Neoplasms - drug therapy Retinoblastoma Retinoblastoma - drug therapy Retrospective Studies Salvage Therapy - methods Treatment Outcome Tumors Veins & arteries Vision Disorders - prevention & control |
| title | First-line intra-arterial versus intravenous chemotherapy in unilateral sporadic group D retinoblastoma: evidence of better visual outcomes, ocular survival and shorter time to success with intra-arterial delivery from retrospective review of 20 years of treatment |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T19%3A11%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=First-line%20intra-arterial%20versus%20intravenous%20chemotherapy%20in%20unilateral%20sporadic%20group%20D%20retinoblastoma:%20evidence%20of%20better%20visual%20outcomes,%20ocular%20survival%20and%20shorter%20time%20to%20success%20with%20intra-arterial%20delivery%20from%20retrospective%20review%20of%2020%E2%80%85years%20of%20treatment&rft.jtitle=British%20journal%20of%20ophthalmology&rft.au=Munier,%20Francis%20L&rft.date=2017-08-01&rft.volume=101&rft.issue=8&rft.spage=1086&rft.epage=1093&rft.pages=1086-1093&rft.issn=0007-1161&rft.eissn=1468-2079&rft_id=info:doi/10.1136/bjophthalmol-2016-309298&rft_dat=%3Cproquest_pubme%3E1847881108%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1919850627&rft_id=info:pmid/27927678&rfr_iscdi=true |